Off-the-shelf and on the decline: Adicet Bio’s shares halved after PhI look at cell therapy
Adicet Bio’s stock price was halved on Tuesday morning as investors tanked the biotech’s shares $ACET following a look at Phase I data on its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
